Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K.A. Foon
Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Analysis of Phase Iiib Magnify Study of Induction R2 Followed by Maintenance in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology